217 related articles for article (PubMed ID: 33942222)
1. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
Chen X; Fan S; Zhao Y; Zhou J
Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.
Jin B; Zhang Y; Hou W; Cao F; Lu M; Yang H; Tian X; Wang Y; Hou J; Fu J; Li H; Zhou J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):485-492. PubMed ID: 31686248
[TBL] [Abstract][Full Text] [Related]
3. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract][Full Text] [Related]
4. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
Poiré X; Moser BK; Gallagher RE; Laumann K; Bloomfield CD; Powell BL; Koval G; Gulati K; Holowka N; Larson RA; Tallman MS; Appelbaum FR; Sher D; Willman C; Paietta E; Stock W
Leuk Lymphoma; 2014 Jul; 55(7):1523-32. PubMed ID: 24160850
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone.
Hou W; Zhang Y; Jin B; Cao W; Lu M; Yan L; Yang H; Tian X; Hou J; Fu J; Zhao H; Li H; Zhou J
Blood Cells Mol Dis; 2019 Nov; 79():102351. PubMed ID: 31400712
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005).
Zhang Y; Wang L; Zhang R; Qi P; Xie J; Shi H; Lin W; Wu Y; Yu J; Fan J; Feng G; Zheng H; Wu M
Pediatr Hematol Oncol; 2019 Oct; 36(7):399-409. PubMed ID: 31530209
[TBL] [Abstract][Full Text] [Related]
8. Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
Abla O; Ribeiro RC; Testi AM; Montesinos P; Creutzig U; Sung L; Di Giuseppe G; Stephens D; Feusner JH; Powell BL; Hasle H; Kaspers GJL; Dalla-Pozza L; Lassaletta A; Tallman MS; Locatelli F; Reinhardt D; Lo-Coco F; Hitzler J; Sanz MA
Ann Hematol; 2017 Sep; 96(9):1449-1456. PubMed ID: 28597167
[TBL] [Abstract][Full Text] [Related]
9. Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.
Wen J; Xu F; Zhou Q; Shi L; Liu Y; Yue J; Zhang Y; Liang X
BMC Cancer; 2023 Jan; 23(1):27. PubMed ID: 36611025
[TBL] [Abstract][Full Text] [Related]
10. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
12. Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
Zhao H; Zhao Y; Zhang Y; Hou J; Yang H; Cao F; Yang Y; Hou W; Sun J; Jin B; Fu J; Li H; Wang P; Ge F; Zhou J
Ann Hematol; 2018 Mar; 97(3):409-416. PubMed ID: 29289982
[TBL] [Abstract][Full Text] [Related]
13. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
Cao F; Li X; Yang Y; Fang H; Qu H; Chang N; Ma Q; Cao W; Zhou J; Wang W
OMICS; 2019 Feb; 23(2):119-130. PubMed ID: 30767729
[TBL] [Abstract][Full Text] [Related]
14. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
Kutny MA; Moser BK; Laumann K; Feusner JH; Gamis A; Gregory J; Larson RA; Powell BL; Stock W; Willman CL; Woods WG; Meshinchi S
Pediatr Blood Cancer; 2012 Oct; 59(4):662-7. PubMed ID: 22378655
[TBL] [Abstract][Full Text] [Related]
15. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
[TBL] [Abstract][Full Text] [Related]
16. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
17. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Hou J; Wang S; Zhang Y; Fan D; Li H; Yang Y; Ge F; Hou W; Fu J; Wang P; Zhao H; Sun J; Yang K; Zhou J; Li X
Ann Hematol; 2017 Dec; 96(12):2005-2013. PubMed ID: 28940056
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
20. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]